Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 15/20 | 0.67 |
| ▸ | CDK6 known ✓ | Q00534 | 5/20 | 0.67 |
| ▸ | PRKD3 known ✓ | O94806 | 3/20 | 0.50 |
| ▸ | PRKCD known ✓ | Q05655 | 3/20 | 0.50 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.50 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.47 |
| ▸ | PRKCA known ✓ | P17252 | 2/20 | 0.47 |
| ▸ | PRKCQ known ✓ | Q04759 | 2/20 | 0.47 |
| ▸ | ACVR1 known ✓ | Q04771 | 2/20 | 0.47 |
| ▸ | ALK known ✓ | Q9UM73 | 2/20 | 0.47 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.47 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.47 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.47 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.47 |
| ▸ | PRKCG known ✓ | P05129 | 1/20 | 0.47 |
| ▸ | PRKCB known ✓ | P05771 | 1/20 | 0.47 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.47 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.47 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.47 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30688749 | 1.00 | CDK4 (0.67) | CDK4CDK1CDK2CCND1CDK9 | |
| Hydrochloric Acid SCHEMBL31632765 | 1.00 | CDK4 (0.67) | CDK4CDK1CDK2CCND1CDK9 | |
| SCHEMBL2446327 | 0.99 | CDK4 (0.68) | CDK4CDK1CDK2CCND1CDK9 | |
| SCHEMBL30688746 | 0.99 | CDK4 (0.68) | CDK4CDK1CDK2CCND1CDK9 | |
| SCHEMBL23682929 | 0.89 | CDK4 (0.71) | CDK4CDK1CDK2CCND1CDK9 | |
| Hydrochloric Acid SCHEMBL665647 | 0.86 | CDK4 (0.66) | CDK4CDK1CDK2CCND1CDK9 | |
| Hydrochloric Acid SCHEMBL3119657 | 0.86 | CDK4 (0.51) | CDK4CDK1CDK2CCND1CDK9 | |
| SCHEMBL666139 | 0.85 | CDK4 (0.65) | CDK4CDK1CDK2CCND1CDK9 | |
| SCHEMBL3108179 | 0.85 | CDK2 (0.51) | CDK4CDK1CDK2CCND1CDK9 | |
| Hydrochloric Acid SCHEMBL3114365 | 0.84 | CDK4 (0.49) | CDK4CDK1CDK2CCND1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383530-B2 | Pharmaceutical combination for the treatment of melanoma | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | disclosed |
| US-20240165076-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2024-05-23 | — | — | US | disclosed |
| CN-117731786-A | Pharmaceutical combination for the treatment of melanoma | 皮拉马尔企业有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11839591-B2 | Pharmaceutical combination for the treatment of melanoma | Piramal Enterprises Limited (IN) | 2023-12-12 | — | — | US | disclosed |
| CN-111053768-B | Pharmaceutical combination for the treatment of melanoma | 皮拉马尔企业有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20210393589-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2021-12-23 | — | — | US | disclosed |
| US-11007174-B2 | Pharmaceutical combination for the treatment of melanoma | Piramal Enterprises Limited (IN) | 2021-05-18 | — | — | US | disclosed |
| CN-111053768-A | Pharmaceutical combination for the treatment of melanoma | 皮拉马尔企业有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-20190282544-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2019-09-19 | — | — | US | disclosed |
| EP-3019166-B1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | PIRAMAL ENTPR LTD (IN) | 2019-05-08 | — | — | EP | disclosed |
| US-20160136132-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2016-05-19 | — | — | US | disclosed |
| EP-3019166-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015004636-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | Piramal Enterprises Limited (IN) | 2015-01-15 | — | — | WO | disclosed |
| EP-2046738-B1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL ENTPR LTD (IN) | 2014-06-11 | — | — | EP | disclosed |
| US-8563596-B2 | Enantiomerically pure compounds for the treatment of proliferative disorders | Piramal Enterprises Limited (IN) | 2013-10-22 | — | — | US | disclosed |
| US-20130237582-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | Piramal Enterprises Limited (IN) | 2013-09-12 | — | — | US | disclosed |
| EP-2046738-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | Piramal Life Sciences Limited (IN) | 2009-04-15 | — | — | EP | disclosed |
| WO-2007148158-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383530-B2 | Pharmaceutical combination for the treatment of melanoma | BRAF, CCNI, CDK1 | CDK4 4/4885CDK6 7/4885PRKD3 298/4885 |
| US-20160136132-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CDK1, CCNI | CDK4 4/4885CDK6 7/4885PRKD3 254/4885 |
| US-20130237582-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | CCNI, CDK1, CDKL1 | CDK4 7/4885CDK6 5/4885PRKD3 328/4885 |
| US-11839591-B2 | Pharmaceutical combination for the treatment of melanoma | BRAF, CCNI, CDK1 | CDK4 4/4885CDK6 7/4885PRKD3 298/4885 |
| US-20190282544-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CCNI, CDK1 | CDK4 4/4885CDK6 7/4885PRKD3 298/4885 |
| US-11007174-B2 | Pharmaceutical combination for the treatment of melanoma | BRAF, CCNI, CDK1 | CDK4 4/4885CDK6 7/4885PRKD3 298/4885 |
| US-20210393589-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CCNI, CDK1 | CDK4 4/4885CDK6 7/4885PRKD3 298/4885 |
| US-20240165076-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | BRAF, CDK1, CDK6 | CDK4 15/4885CDK6 3/4885PRKD3 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.